ICON Issues Financial Guidance for 2009 and Updates Guidance for 2008
Dublin, Ireland--(BUSINESS WIRE)--January 9, 2009--ICON (NASDAQ: ICLR), a global provider of
outsourced development services to the pharmaceutical, biotechnology and medical device industries, today
announced financial guidance for 2009.
2009 net revenue is expected to be in the range of $930 - $980 million. This compares to an expected outcome
of $862 - $865 million for the year ended December 31, 2008, a reduction on previous guidance due to
2009 net income per diluted share is expected to be in the range of $1.40 - $1.52. This compares to $1.27 -
$1.29 for the year ended December 31, 2008, an increase on previous guidance.
The company will hold a conference call today, January 9 th , at 09:00 EST [14:00 Ireland & UK]. A question
and answer session will follow.
The statements made in this Press Release may contain forward-looking statements that involve a number of risks
and uncertainties. In addition to the matters described in this Press Release, the ability to maintain large client
contracts or enter into new contracts, maintain client relationships and the ability to manage the opening of new
offices, the integration of new business mergers and acquisitions, as well as other risks and uncertainties detailed
from time to time in SEC reports filed by ICON, including its Form 20-F, F-1, S-8 and F-3, may affect the
actual results achieved by ICON. ICON disclaims any intent or obligation to update these forward-looking
About ICON plc
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and
medical device industries. The Company specializes in the strategic development, management and analysis of
programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON
teams have successfully conducted over 5,500 development projects and consultancy engagem